MAC-Team

funnelBusiness anc collaboration models are changing in the pharmaceutical and biotechs sector. Open Innovation enters the play with strength.
Being involved in both, in Open innovation and in Biotechs/Pharmaceutical projects, MAC-Team here proposes an outlook of various initiatives in the field.
You can start on Open Innovation, Open source ... aproaches at different levels depending on your strengths, your capacity in leveraging informaiton. You are not obliged to put everything on a plate right from start. you need a clear strategy on that. But, the most successful or fast developing actors are often the ones able to go in the direction of open innovation 2.0. This has been especially true outside the Pharmceutical sector, but this pharmaceutical/biotech sector is now confronted to a suffocating business model. This sector is now going for new business approaches and open innovation is a leading one.
[NB: you can read the full article at once by cliking on "All Pages"  or on a specific page above]

Attachments:
Download this file (Assembling_the_RD_puzzle_FINAL.pdf)Assembling_the_RD_puzzle_FINAL.pdf[Assembling the pharmaceutical R&D puzzle for needs in the developing world (Putgatch Consilium 2012)]1148 kB
Download this file (CEWG_Report_5_April_2012.pdf)CEWG_Report_5_April_2012.pdf[Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (WHO - 2012)]1341 kB
Download this file (oidd_potential_path_ctmc.pdf)oidd_potential_path_ctmc.pdf[Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space (by Lilly)]1033 kB
Access this URL (https://openinnovation.lilly.com/dd/science-of-open-innovation/relevant-publications.html)relevant-publications.html[Publications by Lilly on Open Innovation Drug Discovery]0 kB
Download this file (Open-innovation-a-new-paradigm-for-industry-academia-collaboration.pdf)Open-innovation-a-new-paradigm-for-industry-academia-collaboration.pdf[Open innovation: a new paradigm for industry-academia collaboration, by Paul-Peter Tak, Senior Vice President, Head, Immuno Inflammation Therapy Area, GSK, UK (2013)]2861 kB
Access this URL (http://www.ncbi.nlm.nih.gov/pmc/?term=%22open+innovation%22)pmc[Search on \"open Innovation \" in the journal \"Open Medicine\"]0 kB
Access this URL (http://www.osdd.net)www.osdd.net[OSDD - Open Source Drug Discovery]40 kB